Dr. Wolchok Describes the Immunotherapy Ipilimumab

Jedd D. Wolchok, MD, PhD
Published: Monday, Jun 06, 2011

Jedd D. Wolchok, MD, PhD from Memorial Sloan-Kettering Cancer Center describes the immunotherapy ipilimumab.

Dr. Wolchok says ipilimumab has moved cancer immunotherapy ahead to an important next step. He says high dose Interleukin 2 was the first clear cut example of how pure immune immodulation could lead to control of cancer. The difficulties with IL-2 in terms of side effects and the fact that patients using it sometimes had to be admitted to the hospital limited its use. Although IL-2 is not being compared head to head with ipilimumab, Dr. Wolchok says the kinds of durable responses seen with ipilimumab are reminiscent of immunotherapy. It is an easier drug to give with side effects that, in general, are manageable.
Jedd D. Wolchok, MD, PhD from Memorial Sloan-Kettering Cancer Center describes the immunotherapy ipilimumab.

Dr. Wolchok says ipilimumab has moved cancer immunotherapy ahead to an important next step. He says high dose Interleukin 2 was the first clear cut example of how pure immune immodulation could lead to control of cancer. The difficulties with IL-2 in terms of side effects and the fact that patients using it sometimes had to be admitted to the hospital limited its use. Although IL-2 is not being compared head to head with ipilimumab, Dr. Wolchok says the kinds of durable responses seen with ipilimumab are reminiscent of immunotherapy. It is an easier drug to give with side effects that, in general, are manageable.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x